{"product_id":"transil-bsa-binding-kit","title":"TRANSIL BSA Binding Kit","description":"\u003cdiv class=\"col-12 col-md-12\"\u003e\n    \u003cdiv class=\"text-body\"\u003e\n        \u003cp\u003e\u003cb\u003eDetermination of Drug–Bovine Albumin Binding Constants for Biochemical\nand Cell-Based Assays\u003c\/b\u003e\u003c\/p\u003e\n        \u003cp\u003eThe TRANSIL BSA Binding Kit enables mechanistic characterization of compound\nbinding to bovine serum albumin (BSA), a protein widely used in biochemical assays,\ncell culture systems, and enzyme studies. It determines the binding affinity (KD) of\ntest compounds to BSA under well-defined experimental conditions, enabling\nquantitative analysis of protein binding effects in molecular biology assays and drug\ndiscovery workflows.\u003c\/p\u003e\n        \u003cp\u003e\u003cb\u003eWhy Albumin Binding Matters\u003c\/b\u003e\u003c\/p\u003e\n        \u003cp\u003eMost drug molecules are reversibly bound to proteins in plasma. Only the unbound\nfraction (fu) can cross biological membranes, interact with pharmacological targets,\nor undergo metabolic elimination. Plasma protein binding therefore strongly\ninfluences drug exposure, pharmacokinetics, and pharmacological activity.\u003c\/p\u003e\n        \u003cp\u003eSerum albumin is the most abundant plasma protein in both humans and many\npreclinical species and represents the principal binding partner for many drugs.\nBecause albumin binding can substantially reduce the circulating free drug\nconcentration, accurate characterization of drug–albumin interactions is an important\ncomponent of ADME profiling and lead optimization. Characterizing interactions\nbetween test compounds and BSA is therefore important for interpreting biochemical\nassays and experimental systems where albumin is present.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003eWhy BSA Binding Matters in Biochemical Assays\u003c\/b\u003e\u003c\/p\u003e\n        \u003cul\u003e\n            \u003cli\u003einterpretation of potency in BSA-containing biochemical assays\u003c\/li\u003e\n            \u003cli\u003eestimation of free compound concentrations in enzyme assays\u003c\/li\u003e\n            \u003cli\u003eunderstanding compound binding in FBS-containing cell culture systems\u003c\/li\u003e\n            \u003cli\u003eoptimization of assay buffer composition\u003c\/li\u003e\n            \u003cli\u003eevaluation of nonspecific compound binding to proteins\u003c\/li\u003e\n        \u003c\/ul\u003e\n        \u003cp\u003eThe measured KD provides a quantitative description of compound–albumin\ninteractions and helps estimate free compound concentrations in protein-containing\nassay systems and allows calculation of the free fraction at any BSA concentration.\u003c\/p\u003e\n        \u003cp\u003e\u003cb\u003eBSA in Molecular Biology and Biochemical Assays\u003c\/b\u003e\u003c\/p\u003e\n        \u003cp\u003eBovine serum albumin is widely used in biochemical and cell-based assays. It is\ncommonly included in experimental systems to stabilize enzymes and proteins,\nreduce nonspecific adsorption to surfaces, and mimic protein binding conditions\npresent in biological fluids.\u003c\/p\u003e\n        \u003cp\u003eBecause many small molecules bind strongly to BSA, these interactions can\ninfluence the free compound concentration available in enzymatic assays,\n\nbiochemical screening experiments, or cell culture systems. This is particularly\nrelevant for cell-based assays performed in media containing fetal bovine serum\n(FBS).\u003c\/p\u003e\n\u003cp\u003eIn such systems, binding to albumin can substantially reduce the free concentration\nof test compounds, which may influence apparent potency and assay outcomes.\nDetermining the binding affinity of compounds to BSA therefore helps interpret\nexperimental results and understand how protein binding affects assay performance.\u003c\/p\u003e\n        \u003cp\u003e\u003cb\u003eLimitations of Conventional Plasma Protein Binding Assays\u003c\/b\u003e\u003c\/p\u003e\n        \u003cp\u003eConventional approaches for measuring protein binding, such as equilibrium dialysis,\nultrafiltration, and ultracentrifugation, directly determine the free fraction of a\ncompound in plasma. While widely used, these methods can be time-consuming and\nexperimentally demanding, often requiring long equilibration times and careful\ncontrol of experimental conditions. In addition, adsorption to membranes or plastic\nsurfaces, compound instability, and analytical sensitivity limitations can complicate\nthe accurate measurement of highly bound compounds. These challenges make it\ndifficult to apply traditional methods efficiently in high-throughput drug discovery\nworkflows.\u003c\/p\u003e\n        \u003cp\u003e\u003cb\u003eThe TRANSIL Approach\u003c\/b\u003e\u003c\/p\u003e\n        \u003cp\u003eUnlike plasma-based methods, the TRANSIL approach determines intrinsic\ndrug–albumin binding affinity under controlled conditions, allowing plasma protein\nbinding to be predicted across different physiological albumin concentrations. The\nTRANSIL BSA Binding Kit determines albumin binding affinity by measuring the\ndissociation constant (KD) of the interaction between a test compound and bovine\nserum albumin. In the assay, compounds are incubated with increasing\nconcentrations of albumin immobilized on high-surface-area beads under well-\ndefined experimental conditions. The resulting binding data are used to calculate the\naffinity constant of the drug-albumin interaction, which provides a mechanistic\ndescription of protein binding. Because the KD describes the intrinsic drug–albumin\ninteraction and is independent of protein concentration, it can be used to predict\nplasma protein binding and free drug fraction under physiological conditions and\nacross different albumin concentrations.\u003c\/p\u003e\n        \u003cp\u003e\u003cb\u003eHow the Assay Works\u003c\/b\u003e\u003c\/p\u003e\n        \u003cp\u003eThe assay determines albumin binding affinity through the following experimental\nworkflow:\u003c\/p\u003e\n        \u003col\u003e\n            \u003cli\u003eTest compound is added at constant concentration to 8 wells\u003c\/li\u003e\n            \u003cli\u003eThe compound is incubated with increasing concentrations of bead-\nimmobilized albumin\u003c\/li\u003e\n            \u003cli\u003eBeads are separated, leaving only free drug in solution\u003c\/li\u003e\n            \u003cli\u003eFree drug concentration is quantified (e.g., by LC–MS\/MS)\u003c\/li\u003e\n            \u003cli\u003eBinding affinity (KD) is calculated from the slope of binding versus protein\nconcentration\u003c\/li\u003e\n        \u003c\/ol\u003e\n        \u003cimg alt=\"\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0428\/8554\/6146\/files\/Picture1_1.webp?v=1773040872\" style=\"height: auto; width: 600px;\"\u003e\n        \u003cp\u003e\u003cb\u003eFeatures and Benefits\u003c\/b\u003e\u003c\/p\u003e\n        \u003cul\u003e\n            \u003cli\u003e\n\u003cb\u003eMembrane-free binding measurement\u003c\/b\u003e\n                \u003cp\u003eImmobilization of albumin on beads eliminates the need for dialysis\nmembranes, accelerating equilibration between compound and protein while\navoiding artifacts caused by membrane adsorption or slow diffusion through\ndialysis membranes.\u003c\/p\u003e\n            \u003c\/li\u003e\n            \u003cli\u003e\n\u003cb\u003eRapid equilibrium measurements\u003c\/b\u003e\n                \u003cp\u003eImmobilized albumin on high-surface-area beads enables equilibrium binding\nmeasurements within 12 minutes or less rather than the hours required for\ndialysis-based methods.\u003c\/p\u003e\n            \u003c\/li\u003e\n            \u003cli\u003e\n\u003cb\u003eMechanistic characterization of albumin binding\u003c\/b\u003e\n                \u003cp\u003eDetermines the drug–albumin dissociation constant (KD), providing a\nmechanistic description of the interaction and enabling prediction of plasma\nprotein binding across different physiological protein concentrations.\u003c\/p\u003e\n            \u003c\/li\u003e\n            \u003cli\u003e\n\u003cb\u003eRobust performance for challenging compounds\u003c\/b\u003e\n                \u003cp\u003eAffinity is derived from the relationship between binding and protein\nconcentration, making the method largely insensitive to compound loss\ncaused by nonspecific adsorption or limited recovery.\u003c\/p\u003e\n            \u003c\/li\u003e\n            \u003cli\u003e\n\u003cb\u003eStable and controlled pH conditions\u003c\/b\u003e\n                \u003cp\u003eThe assay is performed in a well-defined buffered environment, preventing\nerrors in free fraction (fu) estimation caused by pH shifts that can occur in\ndialysis experiments.\u003c\/p\u003e\n\u003c\/li\u003e\n            \u003cli\u003e\n\u003cb\u003eWell-defined experimental conditions\u003c\/b\u003e\n                \u003cp\u003eBinding is measured against purified albumin at controlled concentrations,\nreducing variability associated with plasma composition and improving\nreproducibility.\u003c\/p\u003e\n            \u003c\/li\u003e\n            \u003cli\u003e\n\u003cb\u003eHigh-throughput assay format\u003c\/b\u003e\n                \u003cp\u003eThe 96-well format allows analysis of up to 12 compounds per plate,\nsupporting efficient profiling during lead optimization.\u003c\/p\u003e\n            \u003c\/li\u003e\n            \u003cli\u003e\n\u003cb\u003eCompatibility with standard analytical methods\u003c\/b\u003e\n                \u003cp\u003eFree compound concentration can be quantified using LC–MS\/MS, HPLC, or\n\nother commonly used analytical techniques, allowing integration into existing\nworkflows.\u003c\/p\u003e\n            \u003c\/li\u003e\n            \u003cli\u003e\n\u003cb\u003eIntegrated internal quality control\u003c\/b\u003e\n                \u003cp\u003eThe TRANSIL Quality Index (TQI) evaluates data reliability using multiple\nstatistical and experimental metrics, providing an objective assessment of\nassay performance within each experiment.\u003c\/p\u003e\n            \u003c\/li\u003e\n        \u003c\/ul\u003e\n        \u003cp\u003e\u003cb\u003eMethod Validation and Cross-Species Applicability\u003c\/b\u003e\u003c\/p\u003e\n        \u003cp\u003eThe TRANSIL technology has been extensively validated using human serum\nalbumin (HSA), where albumin binding constants determined with the TRANSIL\nassay show strong agreement with plasma protein binding data obtained by\nequilibrium dialysis and reported in the literature.\u003c\/p\u003e\n        \u003cp\u003eBecause the assay measures the intrinsic binding affinity between a compound and\nalbumin, the same experimental principle can be applied to albumin from other\nspecies. The TRANSIL BSA Binding Kit therefore enables mechanistic\ncharacterization of drug binding to bovine serum albumin (BSA) under the same\nwell-defined experimental conditions used for the human assay.\u003c\/p\u003e\n        \u003cp\u003eBecause the assay measures intrinsic compound–albumin binding affinity, the same\nexperimental principle can be applied to albumins from different species and proteins\nused in biochemical assays. Determining binding affinity to BSA therefore provides\nvaluable information for interpreting biochemical assays, enzyme studies, and\nscreening systems where albumin is present.\u003c\/p\u003e\n    \u003c\/div\u003e\n\u003c\/div\u003e","brand":"Sovicell","offers":[{"title":"Default Title","offer_id":52952315330827,"sku":"TPB-0240-2096","price":571.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0428\/8554\/6146\/files\/BSA_image_1.webp?v=1773394151","url":"https:\/\/sovicell.com\/products\/transil-bsa-binding-kit","provider":"Sovicell","version":"1.0","type":"link"}